News | June 28, 2025
Shukra Pharmaceuticals receives LoA from RMSCL
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
